Jonathan Ponciano, The Motley Fool
Wed, April 8, 2026 astatine 8:33 AM CDT 4 min read
Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), reported the merchantability of 38,120 shares of Common Stock for astir $554,000 successful a acceptable of transactions executed connected April 1, 2026 and April 2, 2026, arsenic elaborate successful the SEC Form 4 filing.
| Shares sold (direct) | 38,120 |
| Transaction value | ~$554,000 |
| Post-transaction shares (direct) | 447,202 |
| Post-transaction worth (direct ownership) | ~$6.62 million |
Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($14.53).
-
How does this merchantability subordinate to Rubinstein's wide ownership and capableness for aboriginal sales?
The 38,120 shares sold correspond 7.85% of her nonstop Common Stock holdings arsenic of the transaction date, with 447,202 shares remaining straight owned and further options outstanding for aboriginal conversion. -
What is the derivative discourse for this transaction?
The merchantability progressive the workout of banal options, instantly followed by open-market sales, indicating the disposition was facilitated by conversion, not a nonstop simplification of pre-existing Common Stock. -
Does Rubinstein clasp worldly vulnerability to Adaptive Biotechnologies post-sale?
Yes, she maintains a nonstop holding of 447,202 shares of Common Stock, providing ongoing equity information and alignment with shareholders.
| Revenue (TTM) | $276.98 million |
| Net income (TTM) | -$59.50 million |
| 1-year terms change | 80% |
* 1-year show calculated utilizing April 2nd, 2026 arsenic the notation date.
-
Key products see immunoSEQ, clonoSEQ, and T-Detect COVID, with gross generated from immunosequencing research, objective diagnostics, and illness monitoring services.
-
The institution operates a platform-driven model, leveraging proprietary immune medicine exertion to supply diagnostic and monitoring solutions for oncology, infectious diseases, and autoimmune conditions.
-
Primary lawsuit segments see beingness sciences research, objective diagnostics, and cause find applications.
Adaptive Biotechnologies Corporation is simply a commercial-stage biotechnology institution specializing successful immune-driven diagnostics and monitoring solutions. Its strategy centers connected leveraging a proprietary immune medicine level to alteration earlier and much precise illness detection, supported by collaborations with manufacture leaders specified arsenic Genentech and Microsoft.
With a increasing portfolio of objective and probe products, Adaptive Biotechnologies delivers data-driven solutions to the healthcare and beingness sciences sectors, aiming to beforehand personalized medicine and amended diligent outcomes.

1 hour ago
1



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·